| Dovitinib studied in …STUDIED_INderived35 of 35show fewer |
|---|
| → studied in | NCT01497392Phase 1 · completed Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers · 35 trials list this drug (0 active) | — | — | Adult Solid Neoplasm,Malignant Pancreatic Neoplasm,Pancreatic Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01732107Phase 2 · terminated Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression · 35 trials list this drug (0 active) | — | — | Malignant Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01443481Phase 1 · completed Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function · 35 trials list this drug (0 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01700270Phase 1 · completed Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors. · 35 trials list this drug (0 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01548924Phase 1 · terminated Determination of Dose of Antiangiogenic Multitargeted DOVITINIB (TKI258) Plus Paclitaxel in Patients With Solid Tumors · 35 trials list this drug (0 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01635907Phase 2 · completed Dovitinib in Neuroendocrine Tumors · 35 trials list this drug (0 active) | — | — | Paraganglioma,Adrenal Gland Pheochromocytoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01440959Phase 2 · completed Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST): TKI258 · 35 trials list this drug (0 active) | — | — | Gastrointestinal Stromal Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01719549Phase 2 · completed Dovitinib for Gastric Cancer With FGFR2 Amplification: GASDOVI-1 · 35 trials list this drug (0 active) | — | — | Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01262027Phase 2 · completed TKI258 for Metastatic Inflammatory Breast Cancer Patients · 35 trials list this drug (0 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01994590Phase 2 · terminated Dovitinib (TKI258) and Abiraterone Acetate in Metastatic Castrate-Resistant Prostate Cancer (mCRPC) · 35 trials list this drug (0 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01524692Phase 2 · completed Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma · 35 trials list this drug (0 active) | — | — | Adenoid Cystic Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02116803Phase 2/Phase 3 · completed An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective · 35 trials list this drug (0 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01484041Phase 1/Phase 2 · terminated Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer · 35 trials list this drug (0 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01676714Phase 2 · completed Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer · 35 trials list this drug (0 active) | — | — | Lung Non-Small Cell Carcinoma,Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01753713Phase 2 · completed Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma · 35 trials list this drug (0 active) | — | — | Adult Giant Cell Glioblastoma,Adult Glioblastoma,Adult Brain Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02108782Phase 2 · withdrawn Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors · 35 trials list this drug (0 active) | — | — | Gastrin-Producing Neuroendocrine Tumor,Pancreatic Glucagonoma,Pancreatic Insulinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01514526Phase 2 · completed Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma · 35 trials list this drug (0 active) | — | — | Adrenal Cortical Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01831726Phase 2 · completed Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib · 35 trials list this drug (0 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01266070Phase 2 · terminated TKI 258 in Von Hippel-Lindau Syndrome (VHL) · 35 trials list this drug (0 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01888965Phase 2 · terminated Maintenance Dovitinib for Colorectal and Pancreas Cancer · 35 trials list this drug (0 active) | — | — | Pancreatic Carcinoma,Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01515969Phase 1 · terminated Phase 1 Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer (NSCLC) · 35 trials list this drug (0 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01528345Phase 2 · terminated Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer · 35 trials list this drug (0 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01478373Phase 2 · completed Efficacy and Safety of Dovitinib in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib · 35 trials list this drug (0 active) | — | — | Gastrointestinal Stromal Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01972750Phase 1 · unknown Dovitinib (TKI258) in the Treatment of Patients With Relapsed Glioblastoma · 35 trials list this drug (0 active) | — | — | Glioblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01223027Phase 3 · completed Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma · 35 trials list this drug (0 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01232296Phase 2 · completed A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line Treatment · 35 trials list this drug (0 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01678105Phase 2 · completed A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands · 35 trials list this drug (0 active) | — | — | Malignant Salivary Gland Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01769547Phase 2 · terminated A Phase II Study of Single-agent DOVitinib in Advanced Malignant PlEural Mesothelioma Which Has Progressed Following Prior Platinum-Antifolate Chemotherapy · 35 trials list this drug (0 active) | — | — | Pleural Malignant Mesothelioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01791387Phase 2 · unknown 1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC · 35 trials list this drug (0 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02065323Phase 2 · withdrawn A Study of Dovitinib With Androgen Deprivation Therapy (ADT) in Patients With Metastatic Prostate Cancer Receiving Primary ADT · 35 trials list this drug (0 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02048943Phase 1 · withdrawn Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer · 35 trials list this drug (0 active) | — | — | Adult Solid Neoplasm,Malignant Pancreatic Neoplasm,Pancreatic Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01964144Phase 2 · completed An Open-label, Multicenter, Phase II Study of Dovitinib in Advanced Thyroid Cancer · 35 trials list this drug (0 active) | — | — | Malignant Thyroid Gland Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01714765Phase 1 · completed Dose Escalation Study Investigating Everolimus and Dovitinib in Metastatic Clear Cell Renal Cancer · 35 trials list this drug (0 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01861197Phase 2 · unknown Phase II Study of Dovitinib for FGFR1 Amplified Squamous Non-small Cell Lung Cancer · 35 trials list this drug (0 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01680796Phase 1 · withdrawn Dovitinib Combined With Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma · 35 trials list this drug (0 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |